Texas cannabis policy now runs on two tracks. Consumable hemp businesses face a total-THC testing standard, higher licensing costs, age restrictions, and active litigation. At the same time, the Texas Compassionate Use Program is adding dispensary licenses, satellite access points, dosage forms, and qualifying conditions.
For consumers, “hemp” and “medical cannabis” are not interchangeable legal categories. For businesses, a product that once fit a delta-9-only reading may fail the state’s newer total-THC approach. For patients, Texas still uses a physician-entered prescription in CURT—not a conventional plastic medical card.
What Changed for Consumable Hemp
Rules adopted by the Texas Department of State Health Services took effect March 31, 2026. DSHS says the program now includes age-gating, updated labels and testing, higher fees, and THCA in the total delta-9 THC calculation. That last point matters because THCA can convert to delta-9 THC when heated.
The practical result is a narrower retail lane for products such as high-THCA flower. Manufacturers and retailers should use current DSHS guidance rather than old articles built around the federal 0.3% delta-9 threshold alone. Consumers should not assume that a product marketed as “federally compliant hemp” automatically satisfies Texas rules.
The Medical Program Is Moving in the Other Direction
House Bill 46 expanded the Compassionate Use Program beginning September 1, 2025. Texas DPS describes a system with more dispensing-organization licenses, additional access points, broader qualifying conditions, and new product options. The pathway remains physician-directed: a registered clinician determines whether the potential benefit is reasonable and enters the prescription into CURT.
That distinction is frequently blurred in advertising. Texans do not apply to the state for a recreational-style “card,” and DPS says patients do not pay a state registration fee. They receive a prescription through a participating physician and fill it through a licensed dispensing organization.
Why Critics Call It a Double Standard
The policy tension is visible. One market is treated primarily as retail risk and subjected to product restrictions and steep compliance costs. The other is treated as healthcare and gains institutional support. Yet many consumers are seeking the same outcomes—sleep, pain management, relief from PTSD symptoms, or a predictable low dose.
There are legitimate reasons for different rules. Medical products move through licensed dispensers, patient identities are recorded in CURT, and a clinician is involved. Hemp products reach a much broader population. But policy credibility depends on more than labels: testing quality, accurate dosing, youth access, adverse-event reporting, and honest marketing matter in both systems.
What Texans Should Do Now
- Patients: use the DPS physician directory and confirm that any evaluator participates in the Texas program.
- Hemp shoppers: ask for a recent certificate of analysis and check Texas—not only federal—rules before purchasing.
- Retailers: follow DSHS notices and legal developments; do not rely on a vendor’s compliance claim.
- Everyone: treat fast-changing cannabis headlines as a starting point, not a substitute for the current agency rule.
Our Editorial View
Texas should apply the same core expectations across both channels: independent testing, clear milligram labeling, age controls, realistic risk communication, and proportionate enforcement. A regulated system earns trust when its rules track product risk and consumer behavior—not simply whether a purchase started at a clinic or a store counter.